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Introduction: The enormous biological complexity and high mortal-
ity rate of lung cancer highlights the need for new global approaches 
for the discovery of reliable early diagnostic biomarkers. The study 
of bronchoalveolar lavage samples by proteomic techniques could 
identify new lung cancer biomarkers and may provide promising 
noninvasive diagnostic tools able to enhance the sensitivity of cur-
rent methods.
Methods: First, an observational prospective study was designed 
to assess protein expression differences in bronchoalveolar lavages 
from patients with (n = 139) and without (n = 49) lung cancer, using 
two-dimensional gel electrophoresis and subsequent protein iden-
tification by mass spectrometry. Second, validation of candidate 
biomarkers was performed by bead-based immunoassays with a dif-
ferent patient cohort (204 patients, 48 controls).
Results: Thirty-two differentially expressed proteins were identified 
in bronchoalveolar lavages, 10 of which were confirmed by immuno-
assays. The expression levels of APOA1, CO4A, CRP, GSTP1, and 
SAMP led to a lung cancer diagnostic panel that reached 95% sen-
sitivity and 81% specificity, and the quantification of STMN1 and 
GSTP1 proteins allowed the two main lung cancer subtypes to be 
discriminated with 90% sensitivity and 57% specificity.
Conclusions: Bronchoalveolar lavage represents a promising non-
invasive source of lung cancer specific protein biomarkers with high 
diagnostic accuracy. Measurement of APOA1, CO4A, CRP, GSTP1, 
SAMP, and STMN1 in this fluid may be a useful tool for lung can-
cer diagnosis, although a further validation in a larger clinical set is 
required for early stages.
Key Words: Bronchoalveolar lavage, Proteomics, Biomarker, Lung 
cancer, Immunoassay.
(J Thorac Oncol. 2014;9: 1504–1512)
IntroductIon
Lung cancer remains the most common cause of can-
cer-related deaths worldwide.1 It is divided into two major 
clinicopathological classes: small-cell lung cancer (SCLC), rep-
resenting approximately 15% of cases, and non–small-cell lung 
cancer (NSCLC), which accounts for 85% of cases.2 NSCLC is 
commonly treated with surgery, while SCLC usually responds 
better to chemotherapy and radiotherapy.3 However, the clini-
cal outcome of conventional therapies remains very poor (15% 
5-year survival) mainly due to difficulties with early diagnosis.4
Bronchoscopy can be considered as the primary diag-
nostic method in patients with suspected pulmonary carcinoma 
and is also necessary to select the appropriate therapeutic strat-
egy.5 It is less invasive than other tissue procurement methods, 
carries a small risk of complications, and has high specificity, 
although its sensitivity is relatively poor.5,6 It is expected that 
approaches that do not require the collection of tumor cells, 
such as the detection of molecular markers in bronchial flu-
ids, will enhance the sensitivity of cytological examination 
(30–80% depending on tumor accessibility)6,7 and improve the 
diagnostic accuracy. Traditionally, blood has been the biologi-
cal fluid used for noninvasive biomarker analysis, but detection 
of low-abundance tumor proteins in this complex mixture can 
be very challenging. Bronchoalveolar lavage (BAL) represents 
an alternative source of more specific lung cancer biomark-
ers due to its vicinity to tumor cells, its less complex protein 
composition, and the fact that it can be obtained through mini-
mally invasive methods, compared with biopsies.8 A number 
of potential biomarkers have already been found in bronchial 
fluids from lung cancer patients,5 but few have proved to be 
useful in the clinic, because of their low sensitivity, specific-
ity, and reproducibility.9,10 Thus, identification and validation 
of diagnostic biomarkers for early detection and subtype clas-
sification of lung cancer patients is urgently needed.
Nevertheless, it is not realistic to explain any cancer as 
a disorder of one single protein. Therefore, high-throughput 
molecular techniques could represent an alternative strategy 
for the selection of a panel comprising a combination of dif-
ferent biomarkers. Proteomics, a powerful tool for global 
evaluation of protein expression, has been widely applied in 
cancer research, allowing the efficient identification of accu-
rate and reproducible differentially expressed proteins in com-
plex biological samples.9
Several proteomic studies have used BAL samples to 
assess differential protein profiles in a number of lung-related 
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diseases such as asthma, sarcoidosis, and cystic fibrosis,11 
but the suitability of BAL as a source of NSCLC biomarkers, 
was not reported until 2011 by Oumeraci et al.,8 based on a 
preliminary proof of concept using six lung cancer samples. 
Very recently, Pastor et al.12 have published the first proteomic 
study of NSCLC in BAL using two-dimensional polyac-
rilamide gel electrophoresis (2D-PAGE). However, to date no 
study has evaluated the protein profile of lung cancer BAL by 
2D-PAGE, including both SCLC and NSCLC, and perform-
ing a comprehensive validation of the results with a different 
patient cohort and an alternative technique.
In the present study, BAL samples from lung cancer 
patients (n = 139) were compared with those from subjects with 
nonmalignant pulmonary diseases (n = 49) by 2D-PAGE with 
the aim of finding candidate diagnostic biomarkers. Thirty-two 
proteins significantly up- or down-regulated were identified 
by mass spectrometry (MS). Ten of them were individually 
validated using a different patient cohort and technique (bead-
based immunoassays). Furthermore, a panel comprising five of 
those biomarkers led to a useful tool for an accurate diagnosis 
of lung cancer. Moreover, the quantification of two biomarkers 
was found to differentiate NSCLC and SCLC patients.
MAtErIALS And MEtHodS
Study design
The main objective was to identify protein biomarkers 
that could be useful in the clinics to improve lung cancer-
specific diagnostic. For that purpose, two prospective and 
observational studies were carried out in two phases: (1) a 
biomarker discovery phase, where 188 BAL samples from 
lung cancer patients (n = 139; 43 SCLC and 96 NSCLC) and 
control subjects (n = 49) were subjected to 2D-PAGE analy-
sis, and differentially expressed proteins identified by MS; 
and (2) a biomarker validation and diagnostic model genera-
tion phase, where identified candidate proteins were quanti-
fied in 252 BAL samples (49 control subjects and 204 cancer 
patients, 63 SCLC and 141 NSCLC) by in-solution bead-
based immunoassays. A multivariate model was generated by 
logistic regression analysis.
Study Subjects and Samples
All patients were recruited at Cruces Hospital 
(Barakaldo, Spain). Study protocols were approved by the 
corresponding ethical committee and all patients signed an 
informed consent form. Subjects with suspected lung cancer, 
who were finally diagnosed with another respiratory-related 
disease (including pneumonia, bronchitis, sarcoidosis, and 
chronic bronchopathy) were classified as controls. Patients 
with either SCLC or NSCLC at different clinical stages were 
included. The diagnosis was confirmed by anatomical pathol-
ogy. Characteristics of the study population are summarized 
in Table 1.
BAL specimens were collected during bronchoscopy 
for routine diagnostic purposes, by flushing the airways with 
saline fluid to harvest surrounding cells. After centrifugation 
tAbLE 1.  Patient Demographics and Clinical Profiles
Demographic Characteristics
Discovery Set Validation sestet
Control Patients 
(n = 49)
Cancer Patients 
(n = 139)
Control Patients 
(n = 48)
Cancer Patients 
(n = 204)
Age (mean ± SEM) 56.4 ± 14.5 63.6 ± 10.3 54.9 ± 14.0 63.0 ± 10.7
Sex
  Male 38 123 38 177
  Female 11 16 10 27
Smoking habit
  Nonsmokers 13 5 14 8
  Ever smokers 36 134 34 196
Histology
  SCLC 43 63
  NSCLC 96 141
   Adenocarcinoma 29 59
   Squamous cell carcinoma 64 80
   Others 3 2
Clinical stage
Total (SCLC/NSCLC)
  I 14 (2/12) 14 (2/12)
  II 4 (1/3) 4 (0/4)
  III 47 (13/34) 60 (17/43)
  IV 65 (25/40) 109 (40/69)
  Undetermined 9 (2/7) 17 (4/13)
SEM, standard error of the mean; SCLC, small-cell lung cancer; NSCLC, non–small-cell lung cancer.
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at 3000 rpm for 15 minutes at 4°C supernatants were stored 
frozen at −80°C until analysis.
2d-PAGE
Total protein concentration of each BAL was measured 
by Bradford assay using Bio-Rad Protein Assay (Bio-Rad, 
Hercules, CA). Protein precipitation and 2D-PAGE were con-
ducted as described elsewhere.13 In order to obtain a high spot 
resolution, specific isoelectric focusing conditions for BAL 
specimens were set up: rehydration of the strips was carried 
out at 50 V for 12 hours, and proteins were focused by gradu-
ally increasing the voltage across the immobilized pH gradi-
ent strips up to 10,000 V and maintaining this voltage up to 
120 kVh. After electrophoresis, proteins were stained with 
Silver Staining Kit (GE Healthcare, Little Chalfont, UK) fol-
lowing the manufacturer’s instructions. Each gel was repeated 
at least twice.
Gel Imaging and Analysis
Digitized images of 2D gels were analyzed using 
Progenesis PG220 software (Nonlinear Dynamics, Newcastle 
Upon Tyne, UK). Protein spots were automatically detected 
and manually matched to a reference gel. The background was 
subtracted using the mode of “non-spot.” The total pixel inten-
sity within each spot was determined by the software and each 
spot volume was normalized by the total spot volume.13 Those 
proteins whose expression was significantly up- or down-reg-
ulated by 1.5-fold or greater were identified by MS.
Protein Identification by MS
Spots of interest were excised from gels, and subjected 
to in-gel tryptic digestion and peptide mass fingerprinting on 
a Bruker Autoflex III TOF/TOF mass spectrometer (Bruker-
Daltonics, Bremen, Germany) as described elsewhere.14 
Protein identification was achieved by searching in a nonre-
dundant protein database using the Mascot search engine.
bead-based Immunoassay development  
and Analysis
xMAP Technology (Luminex Corp., Austin, TX) was used 
as an alternative technique for biomarker validation, which is 
based on in-solution sandwich immunoassays. Briefly, capture 
antibodies were coupled to fluorescent beads (Luminex Corp.) 
and detection antibodies were biotin-labelled using Biotin-XX 
reagent (Molecular Probes; Life Technologies, Carlsbad, CA) 
following manufacturers’ instructions. For assay development, 
25 μl of a specific bead-coupled capture antibody were mixed 
with 25 μl sample and 25 μl Chemiblocker buffer (Millipore, 
Billerica, MA) in 96-well Millipore filter plates (Millipore), 
and incubated for 1 hour, on a plate shaker, at room temper-
ature and in the dark. The same incubation conditions were 
used after sequentially adding 25 μl detection antibody and 
25 μl streptavidin-R-phycoerythrin (SAPE; Invitrogen, 
Carlsbad, CA). Finally, after washing twice with 200 μl phos-
phate buffer saline, the mixture was resuspended in Sheath 
Fluid (Luminex Corp.) and read in a Luminex 200 Total 
System. Median fluorescence intensity values were obtained 
by quantifying 100 beads per well.
Immunoassays for the quantification of 10 pro-
teins identified as differentially expressed in BAL (AMBP, 
APOA1, CO4A, CRP, GSTP1, HPT, PRDX2, PUR6, SAMP, 
and STMN1) were set up. Appropriate BAL dilution, cap-
ture antibody, detection antibody, and SAPE concentration 
were individually optimized for each candidate biomarker 
(see Supplemental Table 1, Supplemental Digital Content 
1, http://links.lww.com/JTO/A641), and the performance of 
those immunoassays was validated. Within-run precision was 
assessed by using three determinations of each sample (coef-
ficient of variation <10%) and between-run repeatability was 
evaluated by measuring samples in duplicate, in two different 
days (coefficient of variation <20%).
Statistical Analysis and diagnostic 
Model Generation
In the discovery phase of the study, significant dif-
ferences in protein expression levels were determined by 
Student’s t test with a set value of p value less than 0.05 for 
the following comparisons: Control versus All the patients 
with lung cancer, Control versus NSCLC, Control versus 
SCLC, and NSCLC versus SCLC. In the validation study, the 
most clinically relevant comparisons, Control versus Total 
lung cancer and SCLC versus NSCLC, were performed and 
Student’s t test p values were calculated. The area under the 
receiver operating characteristic curves (AUC), fold change, 
sensitivity (Se), specificity (Sp), positive predictive value, 
and negative predictive value were also calculated for each 
protein using Analyse-it software (Leeds, UK). In addition, 
differences in the amount of proteins between smokers and 
nonsmokers and at different cancer stages were assessed.
Validated lung cancer biomarkers were analyzed by 
logistic regression and stepwise forward selection was per-
formed to determine the combination of biomarkers with the 
best diagnostic parameters, using SPSS 11.0 software (SPSS 
Inc., Chicago, IL). Se, Sp, positive predictive value, and nega-
tive predictive value for the biomarker combinations were 
determined for the diagnostic model.
rESuLtS
Identification of differentially 
Expressed Proteins by 2d-PAGE
BAL samples from 49 control subjects and 139 lung can-
cer patients (43 SCLC and 96 NSCLC, Discovery set; Table 
1) were subjected to 2D-PAGE. In the 188 gels studied, an 
average of 373 spots per gel were analyzed (only those pres-
ent in at least 75% of samples). In the comparison “Control” 
versus “All the patients with lung cancer,” 49 spots showed 
statistically significant differences in staining intensity. When 
Control versus NSCLC, Control versus SCLC, and NSCLC 
versus SCLC were compared, 26, 18, and 12 spots, respec-
tively were found over/down-regulated. Some examples of spe-
cific spots are shown in Supplemental Figure 1 (Supplemental 
Digital Content 2, http://links.lww.com/JTO/A642). In total, 
51 spots were differentially stained in at least one of the four 
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comparisons performed (Fig. 1). Forty-eight of these spots 
were successfully identified by MS. In some cases, different 
spots were identified as the same protein, giving rise to a total 
of 32 different lung cancer candidate biomarkers (Table 2).
According to diverse databases (UniprotKB, DAVID, 
GATHER, Ingenuity Pathways), all these proteins collectively 
participate in multiple biological functions in the organism, such 
as metabolic processes, cell death, molecular transport, inflamma-
tory response, and cell proliferation, all processes found disregu-
lated in cancer development. Interestingly, 13 of these proteins 
had not previously been associated specifically with lung cancer 
(ACTY, ADH7, AK1A1, ANXA4, APOA1, BLVRB, DDAH1, 
F16P1, NDK5, PRDX5, RSPH9, RUVB2, and TALDO) and 
seven (ACTY, ANXA4, NDK5, PARK7, PUR6, RSPH9, and 
RUVB2) have never been detected in human BAL.
candidate biomarker Validation 
by Immunoassays
With the aim of confirming the differential expression 
levels of candidate biomarkers found by 2D-PAGE, in-solu-
tion sandwich immunoassays were set up for individual bio-
markers and a different set of BAL samples (48 Control, 141 
NSCLC, 63 SCLC; Validation set; Table 1) was used. Among 
the 32 identified proteins, those with a fold-change greater 
than 2 were selected for validation (Table 2). After having 
generated and tested a great deal of antibodies against the 20 
proteins selected, 10 functional antibody pairs were obtained 
from commercial vendors or in-house antibody production 
(see the Supplemental Table 1, Supplemental Digital Content 
1, http://links.lww.com/JTO/A641). This clearly evidences 
that it resulted extremely difficult to obtain antibody pairs that 
specifically bind to different epitopes of the protein isoform 
present in BAL specimens at the same time.
Significant expression changes of nine biomarkers 
(AMBP, APOA1, CO4A, CRP, GSTP1, HPT, PRDX2, PUR6, 
and SAMP) were confirmed when comparing control with 
total lung cancer samples. In addition, four proteins (CRP, 
GSTP1, SAMP and STMN1) were differentially expressed 
according to lung cancer subtype (SCLC or NSCLC) (Table 3 
and Supplemental Table 2, Supplemental Digital Content 
3, http://links.lww.com/JTO/A643). SAMP gave rise to the 
best individual biomarker able to detect lung cancer patients 
(95% Se, 66% Sp), while STMN1 showed the best diagnostic 
potential to distinguish between lung cancer subtypes (90% 
Se, 52% Sp). Statistical and diagnostic parameters for each 
protein and comparison are shown in Table 3.
No effect on the expression profile was observed due to 
smoking habits for any of the validated proteins, except for CRP 
which was significantly increased in smoker Control patients 
compared to nonsmoker Control patients. Still, the CRP level 
was significantly higher in nonsmoker patients with lung cancer 
than in the smoker control population (data not shown).
cancer Stage
In order to evaluate the diagnostic capacity of our bio-
markers according to cancer progression status, biomarker 
level was also investigated according to the cancer stage. 
Analysis of variance showed that for all biomarkers the 
FIGurE 1.  Representative silver-
stained proteome of a bronchoalveo-
lar lavage sample. The 51 selected 
spots are circled in red. The main 
information of each spot is listed in 
Table 2.
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differences between control and cancer samples were signifi-
cant at early stages (I + II) (p ≤ 0.05) (Fig. 2), suggesting that 
expression levels of these biomarkers could be a potential tool 
for reaching lung cancer diagnosis at earliest stages.
Biomarker expression differences at each cancer stage 
according to histology (SCLC versus NSCLC) were also ana-
lyzed (Supplemental Fig. 2, Supplemental Digital Content 4, 
http://links.lww.com/JTO/A644). The results of this compari-
son were quite similar for every biomarker regardless the cancer 
subtype, although it has to be mentioned that the small number 
of SCLC patients at early stages (I and II) and NSCLC patients 
at stage II did not allow a reliable separated analysis. STMN1 
expression was not significantly different among controls and 
NSCLC patients at any stage, as could have been expected since 
this is a biomarker for specific SCLC patients detection.
development of a biomarker Panel 
for Lung cancer diagnosis
When comparing samples collected from control sub-
jects with those from lung cancer patients, a panel comprising 
APOA1, CO4A, CRP, GSTP1, and SAMP was selected, which 
reached 95% Se and 81% Sp, with an AUC of 0.94 (Fig. 3A). 
The algorithm was able to correctly classify 38 of 46 controls 
and 168 of 177 lung cancer patients. A biomarker panel to 
discriminate between the main lung cancer subtypes, SCLC 
and NSCLC, was also generated, which comprised STMN1 
and GSTP1, and reached 90% Se and 57% Sp, and an AUC of 
0.80. Thirty-five of 49 SCLC patients and 127 of 155 NSCLC 
patients were correctly classified (Fig. 3B).
tAbLE 2.  Identified Human BAL Proteins with Significant Expression Changes in Lung Cancer
Spot No ID Protein Abbreviation (Protein Full Name) Cancer NSCLC SCLC
1 P42025 ACTY (Beta-centractin) −1.96 −2.06 −1.85
2 P40394 ADH7 (Alcohol dehydrogenase class 4 mu/sigma chain) −2.18 −2.48 n.s.
3, 4 P14550 AK1A1 (Alcohol dehydrogenase [NADP(+)]) −2.08 −2.07 −2.18
5 P02760 AMBP (Protein AMBP) 4.76 4.85 4.55
6 P09525 ANXA4 (Annexin A4) −1.74 −1.80 −1.61
7 P08758 ANXA5 (Annexin A5) −1.65 −1.76 n.s.
8–12 P02647 APOA1 (Apolipoprotein A-I) 51.84 68.59 28.95
13, 14 P30043 BLVRB (Flavin reductase (NADPH)) 1.76 1.86 n.s.
15 Q9NP55 BPIA1 (BPI fold-containing family A member 1) −2.30 −2.68 n.s.
16 P40121 CAPG (Macrophage-capping protein) n.s. n.s. −1.96
17 P0C0L4 CO4A (Complement C4-A) 2.90 3.48 1.95
18 P02741 CRP (C-reactive protein) 3.08 3.64 2.18
19 O94760 DDAH1 (N(G),N(G)-dimethylarginine dimethylaminohydrolase 1) 1.70 1.77 1.57
20 P09467 F16P1 (Fructose-1,6-bisphosphatase 1) −1.90 −1.91 −1.93
21 P52566 GDIR2 (Rho GDP-dissociation inhibitor 2) −2.27 −2.63 −1.67
22 P07203 GPX1 (Glutathione peroxidase 1) −1.92 −2.12 n.s.
23 P09210 GSTA2 (Glutathione S-transferase A2) −1.50 −1.66 n.s.
24 P09211 GSTP1 (Glutathione S-transferase P) −2.99 −3.23 −2.54
25–30 P00738 HPT (Haptoglobin) 12.78 18.20 6.32
31 P56597 NDK5 (Nucleoside diphosphate kinase homolog 5) −2.41 −2.51 −2.24
32 Q99497 PARK7 (Protein DJ-1) −1.70 −1.82 −1.50
33, 34 P32119 PRDX2 (Peroxiredoxin-2) 2.98 3.24 2.48
35 P30044 PRDX5 (Peroxiredoxin-5, mitocondrial) −1.62 −1.68 −1.55
36 Q15257 PTPA (Serine/threonine-protein phosphatase 2A activator) −1.95 −2.11 −1.65
37 P22234 PUR6 (Multifunctional protein ADE2) 2.15 2.40 1.64
38 Q9H1X1 RSPH9 (Radial spoke head protein 9 homolog) −2.83 −3.44 n.s.
39 Q9Y230 RUVB2 (RuvB-like 2) 1.83 1.88 1.84
40, 41 P02743 SAMP (Serum amyloid P-component) 8.32 10.23 5.28
42, 43 P29508 SPB3 (Serpin B3) −1.95 −1.90 −1.85
44 P16949 STMN1 (Stathmin) 4.39 2.52 21.48
45–47 P37837 TALDO (Transaldolase) −2.23 −2.33 −2.01
48 P02766 TTHY (Transthyretin) 1.91 1.61 n.s.
The values shown in last three columns correspond to intensity fold-changes of a particular protein in Cancer vs. Control comparison (either all the cancer samples grouped together 
or subdivided by cancer type, NSCLC or SCLC). Negative values indicate proteins down-regulated in Cancer compared with Controls. When different spots were identified as the same 
protein, the highest fold-change is shown.
ID, accession number obtained from Protein Knowledgebase (UniProtKB); n.s., no statistically significant differences found; BAL, bronchoalveolar lavage; SCLC, small-cell lung 
cancer; NSCLC, non–small-cell lung cancer.
1509Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 10, October 2014 A New Biomarker Panel in Bronchoalveolar Lavage
dIScuSSIon
The extremely high mortality associated with late detec-
tion of lung cancer makes it necessary to identify early diag-
nostic biomarkers that enhance the specificity of cytological 
examination of BAL. This is the first study addressing bio-
marker discovery in human BAL for lung cancer detection 
using 2D-PAGE that includes patients with the two main 
lung cancer subtypes (SCLC and NSCLC). Our results dem-
onstrate that a differential proteomic approach can be highly 
useful for the discovery of specific lung cancer biomarkers. 
Furthermore, this work demonstrates, for the first time, the 
presence of seven proteins (ACTY, ANXA4, NDK5, PARK7, 
PUR6, RSPH9, and RUVB2) in human BAL, leading to an 
important advance in the knowledge of the protein composi-
tion of this fluid.
FIGurE 2.  Influence of cancer 
stage. Box plots represent the 
amount of protein (logarithm values 
of MFIs) in the vertical axis and 
the different cancer stages in the 
abscissa. In gray, values of the control 
samples (0, n = 48) are shown, 
whereas in black the values of the 
samples from patients with lung 
cancer distributed by disease stage 
(I + II, n = 18; IIIA, n = 24; IIIB, n = 
36; and IV, n = 109) are represented. 
*Analysis of variance p value of 0.05 
or less when comparing controls with 
cancer patients at different stages. 
MFIs, median fluorescence intensities.
tAbLE 3.  Individual Statistical and Diagnostic Parameters of Validated Biomarkers
Comparison Protein FC p Value AUC (95% CI) Se Sp PPV NPV
Control vs. Cancer AMBP +4.3 2E-11 0.83 (0.76–0.89) 95 8 81 27
APOA1 +1.8* 2E-03 0.70 (0.61–0.78) 95 17 83 42
CO4A +1.7* 7E-07 0.74 (0.65–0.82) 95 24 80 83
CRP +3.6 3E-09 0.87 (0.80–0.94) 95 64 92 73
GSTP1 −2.0 8E-04 0.78 (0.71–0.85) 95 21 84 48
HPT +6.4 5E-13 0.85 (0.78–0.91) 95 58 91 72
PRDX2 +2.0 2E-06 0.79 (0.70–0.88) 95 50 89 69
PUR6 +3.1 4E-06 0.69 (0.61–0.78) 95 13 82 35
SAMP +5.8 4E-14 0.88 (0.83–0.94) 95 66 92 74
SCLC vs. NSCLC CRP +1.3 0.03 0.57 (0.48–0.65) 90 10 69 30
GSTP1 −1.1 6E-03 0.69 (0.61–0.77) 90 30 74 58
SAMP +1.9 2E-04 0.60 (0.52–0.68) 90 17 71 44
STMN1 −5.5 5E-04 0.76 (0.68–0.85) 90 52 81 70
FC dividing the mean of protein concentration (ng/ml) between study groups; negative values indicates a lower concentration in cancer than controls for the first comparison or in 
NSCLC than SCLC in the second comparison.
* Median fluorescence intensity between groups are divided instead of protein concentrations, since no recombinant antigen was obtained.
AUC, area under the curve (lower and upper limits of 95% CI); Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; FC, fold-change; CI, 
confidence interval.
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Previous studies had already shown the implication 
of some of the proteins identified in this work in lung can-
cer development, such as CAPG,15 GDIR2,16 SERPINB3,17 
annexins,18 or PTPA.19 In the present study, we have identi-
fied 13 proteins not previously related specifically to lung 
cancer, such as DDAH1,20 related to increased tumor growth 
and vascularization; RUVB2,21 overexpressed in different 
types of cancer; or TALDO,22 implicated in oxidative stress, 
inflammation, and carcinogenesis. Additionally, our study has 
related RSPH9 protein, a component of the axonemal radial 
spoke heads present in cilia and flagella23 to cancer for the first 
time. It is known that respiratory infections leading to chronic 
inflammation and bronchiectasis are recurrent, due to defects 
in the respiratory cilia, which may give rise to tumorigenesis.
Aware of reported limitations of 2D gels in terms of repro-
ducibility, an improved isoelectric focusing protocol was spe-
cifically set up for BAL specimen (see Materials and Methods 
section, 2D-PAGE). Moreover, we have analyzed a total of 188 
BAL samples in duplicates, which is the highest number of 2D 
gels performed within a published work to the best of our knowl-
edge. After identification of differentially expressed proteins, we 
selected those with the highest ratio of expression, and tried to 
develop sandwich immunoassays that could quantify the native 
proteins present in BAL specimens. We were able to validate 
10 of these proteins with in-solution bead-based immunoassay, 
which is a versatile and sensitive technology that is currently 
being adopted in several areas of human diagnostics.
Among the validated proteins, we have confirmed the 
previously reported over-expression of CRP and HPT acute-
phase proteins in lung cancer patients,2,24 as well as CO4A 
complement factor,25 indicating a chronic active inflammation 
state and immune response. Recent proteomic studies showed 
alterations of different acute-phase proteins in distinct tumor 
types, which enhanced their usefulness as specific cancer bio-
markers.2 We also detected, for the first time, a significant 
increase of SAMP in lung cancer BAL, in accordance with 
increased serum levels of this protein detected in transgenic 
lung cancer animal models.26 SAMP showed the highest 
individual diagnostic capacity among all the validated proteins 
in this study (95% Se; 66% Sp), and has been demonstrated 
not to act as an acute-phase protein.27 We also detected a sig-
nificantly increased amount of AMBP and PRDX2, probably 
associated with the activation of protection systems against 
reactive oxygen species in the vicinity of tumors, since their 
expression in lung cancer tissue samples has been reported to 
be down-regulated.28,29 Additionally, we confirmed the over-
expression in patients of APOA1 and PUR6, proteins impli-
cated in lipid and purine metabolism, respectively, linked to 
an increased metabolic activity of rapidly proliferating cells. 
As previously mentioned, PUR6 has never been found in 
BAL samples before, and its relation to lung cancer has only 
been described at messenger ribonucleic acid (mRNA) level 
in squamous cell lung carcinoma tissues.30 Besides, PUR6 
may become an attractive target for rational anticancer drug 
design, since rapidly dividing cancer cells rely heavily on the 
purine de novo biosynthetic pathway, whereas normal cells 
favor the salvage pathway.30 Finally, GSTP1 was the only 
validated biomarker with reduced expression in lung cancer 
patients, providing supplementary information to our results. 
GSTP1, a major detoxification enzyme and stress response 
signalling protein, is an important part of the cellular defense 
against endogenous and exogenous chemicals such as chemi-
cal carcinogens and chemotherapeutic drugs.31 Several 
studies have reported a deregulation of this protein in lung 
cancer, associated with the chemosensitivity and prognosis 
of the patients.32,33 The polymorphism and promoter methyla-
tion of GSTP1 gene and their biological significance in lung 
cancer have also been widely studied.34,35 Interestingly, in 
accordance with our results, Zeng et al.36 reported for the first 
time a down-regulation of GSTP1 in the tissue of squamous 
cell carcinomas, and established a role of this protein in the 
carcinogenesis process, suggesting its use as a biomarker for 
early cancer detection. Moreover, very recently Pastor et al.12 
also detected a decreased expression of GSTP1 in a subset of 
15 BAL samples from NSCLC patients, further supporting 
our findings.
FIGurE 3.  Performance of a bio-
marker panel for lung cancer diagno-
sis (box plot of the logistic regression 
values, corresponding receiver oper-
ating characteristic curves and con-
tingency tables). A, Control versus 
Cancer comparison; (B) SCLC versus 
NSCLC comparison. SCLC, small-cell 
lung cancer; NSCLC, non–small-cell 
lung cancer; PPV, positive predictive 
value; NPV, negative predictive value; 
AUC, area under the curve.
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In addition to the above, the combination of five of the 
identified biomarkers (APOA1, CO4A, CRP, GSTP1, and 
SAMP) allowed an accurate detection of lung cancer in BAL 
(95% Se, 81% Sp), which justifies its utility as a complemen-
tary diagnostic tool.
Since the main challenge in the clinics is to prevent lung 
cancer development and progression by detecting it at early 
stages, it was of great interest to know the variation of the amount 
of the abovementioned biomarkers in different clinical stages of 
cancer. Although the number of samples collected in nonad-
vanced stages was quite small, it was interesting to observe that 
alterations in the expression of all the biomarkers were already 
significant at the earliest stages. Moreover, the amount of protein 
was very similar among different stages of the disease, and sig-
nificantly different to the control samples. This strongly suggests 
that the quantification of these proteins in BAL might identify 
patients with operable tumors even though a further validation 
with a larger number of patients is required for early stages.
Lung cancer-specific subtype distinction is extremely 
important for an adequate treatment selection, since the bio-
logical aggressiveness, responsiveness to therapeutic interven-
tion and patients’ prognoses are significantly different between 
lung cancer subtypes.4 The biomarkers CRP, GSTP1, and 
SAMP were demonstrated to be differentially expressed when 
comparing NSCLC and SCLC patients, but STMN1, an onco-
protein with a role in microtubule dynamics, showed the best 
performance as subtype specific biomarker, due to its marked 
overexpression in SCLC BAL samples. Previous studies have 
detected STMN1 over-expression in SCLC cell membrane in 
tissues and different cell lines,37 as well as correlated with poor 
lung carcinoma differentiation,38 and it has been proposed as 
an anticancer therapeutic target.39 Our findings demonstrate for 
the first time its specific over-expression in human SCLC BAL, 
probably due to the highly proliferative state of this cancer 
subtype, and could provide important information for a more 
accurate diagnosis. Furthermore, the combined quantification 
of STMN1 and GSTP1, allowed for an improved discrimina-
tion between NSCLC and SCLC. Although a receiver oper-
ating characteristic curve comparison between STMN1 alone 
(AUC = 0.76) and the combination of GSTP1 and STMN1 
(AUC = 0.80) did not reach significance (data not shown), 
important differences were detected in the number of correctly 
classified SCLC patients. In fact, STMN1 alone led to a total of 
85 correctly classified patients out of 204, whereas the model 
reached 114 correctly classified patients, which is a 14% more 
patients correctly classified. For this reason, authors suggest 
that both biomarkers are taken into account for a future valida-
tion of this model in a new sample cohort.
Taken together, the data presented in this study show 
that BAL is a useful sample for lung cancer biomarker discov-
ery. The proteins identified in this study, and in particular the 
panel of validated biomarkers could be used in the near future 
as a reliable molecular diagnostic tool for lung cancer early 
detection in noninvasive BAL fluids. This algorithm could 
help refine the results of cytological analysis where no cancer 
cells are collected, and enhance the specificity of image-based, 
highly sensitive, diagnostic techniques, where the detection of 
false positives involves unnecessary operations.40 Moreover, 
assuming some correlation of BAL markers and their blood 
levels, a serum-based detection of these biomarkers remains 
a potentially feasible aim. In fact, increased HPT and CRP 
levels in the serum of lung cancer patients have already been 
detected before.24,41 Newly identified lung cancer-associated 
proteins could also represent novel molecular targets for ther-
apeutic intervention and, therefore, could allow the develop-
ment of more rational and effective treatments.
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